Grace Collins

Grace Collins

Auto-generated profile, based on publicly available information

Grace Collins

Friends of Cancer Research, Washington, DC

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GCGrace Collins
Grace Collins
BMBrittany McKelvey
Brittany McKelvey
Hillary Stires AndrewsHillary Stires Andrews
Hillary Stires Andrews
JAJeff D. Allen
Jeff D. Allen
MSMark Stewart
Mark Stewart
The FDA's Oncology Center of Excellence's (OCE) launch of Project Optimus signals increased focus on dose optimization approaches in oncology drug development, particularly toward optimization in the premarket setting. Although sponsors continue to adapt premarket study designs and approaches to align with FDA's expectations for dose optimization, including consideration of the optimal dosage(s), there are still instances where questions remain at the time of approval about whether the approved doses or schedules are optimal. In these cases, FDA can exercise regulatory flexibility by issuing postmarketing requirements (PMR) and avoid delaying patient access to promising therapies. This landscape analysis demonstrates that over the past decade (2012–2022), FDA frequently used PMRs to answer additional questions about dosing for novel oncology approvals. We found more than half of drugs (78/132, 59.1%) had a dosing PMR and observed a recent increase in PMRs intended to evaluate whether a lower dose could be more optimal. These results suggest there are opportunities to adapt premarket dose optimization strategies and leverage innovative development tools to ensure timely identification of the optimal dose.

26 October 2025 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
GCGrace Collins
Grace Collins
JAJeff D. Allen
Jeff D. Allen
HAHillary S. Andrews
Hillary S. Andrews
BNBernat Navarro-Serer
Bernat Navarro-Serer
MSMark D. Stewart
Mark D. Stewart
Background: The Biomarker Qualification Program (BQP), formally established in 2016 under the 21st Century Cures Act , is a key pathway for developing novel biomarkers for regulatory use. We evaluated eight years of BQP experience to assess whether it has facilitated the qualification of novel biomarkers. Methods: We collected characteristics and submission dates for accepted biomarker qualification projects from the FDA’s Drug Development Tool Qualification Project Search database. Results: As of July 1, 2025, 61 projects were accepted into the BQP. Safety (30%), Diagnostic (21%), and PD Response (20%) biomarkers were the most common. Projects primarily used molecular (46%) and radiologic/imaging (39%) methods and were split between measures of a disease/condition or drug response/effect of exposure. Few projects included surrogate endpoint biomarkers ( n = 5). Half of the accepted projects remained at the initial Letter of Intent (LOI) stage, and only eight biomarkers were qualified through the program. LOI and Qualification Plan (QP) reviews frequently exceeded FDA targets by three months and seven months, respectively. For projects reaching the QP stage, QP development took a median of 32 months, with surrogate endpoints taking 47 months. Conclusion: The BQP supports the development of certain biomarkers but has seen limited use for biomarkers intended as surrogate endpoints. Coupled with longer timelines for their QP development, these trends demonstrate the program may not be well-suited for advancing novel response biomarkers. Given significant stakeholder interest in novel surrogate measures, a dedicated program may better support novel response biomarker development, particularly for biomarkers with applicability across multiple drug development programs.

15 July 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GCGrace Collins
Grace Collins
Hillary Stires AndrewsHillary Stires Andrews
Hillary Stires Andrews
BMBrittany McKelvey
Brittany McKelvey
CRCarrigan Rice
Carrigan Rice
JAJeff D. Allen
Jeff D. Allen
MSMark Stewart
Mark Stewart
Clinical trials supporting oncology drug approvals frequently underrepresent diverse racial and ethnic populations. Recent policies have focused on ensuring premarket clinical trials are more inclusive and representative of racial and ethnic diversity in the general U.S. population or intended patient population; however, recent U.S. Food and Drug Administration (FDA) guidance on postmarketing approaches to collecting data in underrepresented populations demonstrates that, in certain circumstances, postmarketing requirements and/or commitments (PMR/Cs) may be issued to conduct more representative studies if there are remaining questions about safety or efficacy. This analysis demonstrates that prior to 2020, no drugs had PMR/Cs to further characterize use in a more representative population, and in the last 3 years, more than half of novel oncology approvals have had such a PMR/C (21/40, 53%). In addition, this analysis helps to identify characteristics, such as single-arm pivotal trial design, U.S. enrollment, and results of safety subgroup analyses based on race and ethnicity, that may contribute to decisions to issue a PMR/C to conduct a study that is more representative of the racial and ethnic diversity of the U.S. or intended patient population. These results can inform efforts to improve premarket clinical trials to ensure they are representative and able to characterize use in any patient who may need the drug.

3 July 2026 in Health Affairs Scholar
Verified
Journal Article
Open access
GCGrace Collins
Grace Collins
DPDivita Pandita
Divita Pandita
HAHillary Andrews
Hillary Andrews
BNBernat Navarro-Serer
Bernat Navarro-Serer
ELElena Levi-D’ANcona
Elena Levi-D’ANcona
MSMark Stewart
Mark Stewart
Introduction: The United States and China are among the largest hubs for oncology drug development and commercialization. We conducted a comprehensive characterization of how the 2 largest oncology drug markets are evolving relative to one another, with implications for regulators, sponsors, clinicians, and patients. Methods: Using publicly available drug databases from the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA), we collected information on novel oncology approvals in the United States and China from 2020 to 2025. Results: From 2020 to 2025, the FDA approved 87 oncology drugs, whereas the NMPA approved 94; most (87% FDA and 65% NMPA) were approved through expedited mechanisms. From 2023 to 2025, the NMPA's approval volume increased and exceeded that of the FDA. Overall, the FDA reviewed drugs a median of 182 days faster, approved them a median of 164 days earlier, and had more global first-in-class approvals. Conclusion: As regulatory capacity expands globally, cross-national comparisons help identify approaches that are working well and inform continued innovation and regulatory modernization in the United States to ensure timely patient access to innovative oncology therapies.

1 July 2026 in JCO Oncology Advances
Verified
Journal Article
Open access
ELElena Levi-D’ANcona
Elena Levi-D’ANcona
Hillary Stires AndrewsHillary Stires Andrews
Hillary Stires Andrews
GCGrace Collins
Grace Collins
BNBernat Navarro-Serer
Bernat Navarro-Serer
JAJeff D. Allen
Jeff D. Allen
MSMark Stewart
Mark Stewart
PURPOSE: Circulating tumor DNA (ctDNA) is an emerging biomarker for early, minimally invasive treatment response assessment, but heterogenous sampling schedules, assay methods, and molecular response (MR) definitions have slowed progress toward regulatory acceptance of ctDNA reductions as an early end point. METHODS: We conducted a landscape assessment of studies evaluating on-treatment ctDNA dynamics within 6 months of therapy initiation and their association with overall survival (OS) or progression-free survival. A total of 162 studies across advanced solid tumors met the inclusion criteria, and four meta-analyses were reviewed separately. We extracted data on cancer type, treatment modality, ctDNA collection timing, assay methodology, and MR definitions to characterize methodological patterns across studies. RESULTS: Among the 76 studies reporting hazard ratios for on-treatment ctDNA dynamics and associations with OS, all but one demonstrated a positive association between ctDNA reductions and improved OS, independent of cancer type, treatment modality, assay platform, or MR definition. Most studies collected ctDNA between 3 and 8 weeks after treatment initiation or at the start of cycle 2 or 3, and next-generation sequencing was the predominant assay used. Although ctDNA clearance yielded the strongest associations, ≥50% decrease and any decrease in ctDNA from baseline were also consistently prognostic, whereas increases in ctDNA were associated with poorer OS. Additionally, all four meta-analyses reported significant associations between ctDNA decrease or clearance and improved OS. CONCLUSION: Early reductions in ctDNA are associated with improved OS across diverse tumor types and therapeutic contexts, underscoring the robustness of ctDNA dynamics as a prognostic biomarker in clinical trials. Standardization of collection timing, MR thresholds, and assay approaches will be essential for advancing on-treatment ctDNA reductions toward regulatory qualification as an early end point.